Publications by authors named "A Paasinen-Sohns"

Unlabelled: Blood-borne metastasis of breast cancer involves a series of tightly regulated sequential steps, including the growth of a primary tumor lesion, intravasation of circulating tumor cells (CTC), and adaptation in various distant metastatic sites. The genes orchestrating each of these steps are poorly understood in physiologically relevant contexts, owing to the rarity of experimental models that faithfully recapitulate the biology, growth kinetics, and tropism of human breast cancer. Here, we conducted an in vivo loss-of-function CRISPR screen in newly derived CTC xenografts, unique in their ability to spontaneously mirror the human disease, and identified specific genetic dependencies for each step of the metastatic process.

View Article and Find Full Text PDF

Gastric adenocarcinoma (GAC) is a heterogeneous disease and at least two major studies have recently provided a molecular classification for this tumor: The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ARCG). Both classifications quote four molecular subtypes, but these subtypes only partially overlap. In addition, the classifications are based on complex and cost-intensive technologies, which are hardly feasible for everyday practice.

View Article and Find Full Text PDF
Article Synopsis
  • Circulating tumor cells (CTCs) can come from solid tumors as either single cells or clusters, with clusters having a higher potential to spread cancer (metastasize).
  • Research shows that most CTC clusters from breast cancer are in low-oxygen (hypoxic) environments, while single CTCs exist in normal oxygen levels (normoxic).
  • Targeting vascular endothelial growth factor (VEGF) reduces primary tumor size but increases hypoxia, leading to more CTC cluster shedding and metastasis, while treatments that encourage blood vessel growth (pro-angiogenic) increase tumor size but reduce CTC cluster formation and metastasis.
View Article and Find Full Text PDF

Companion diagnostics rely on genomic testing of molecular alterations to enable effective cancer treatment. Here we report the clinical application and validation of the Oncomine Focus Assay (OFA), an integrated, commercially available next-generation sequencing (NGS) assay for the rapid and simultaneous detection of single nucleotide variants, short insertions and deletions, copy number variations, and gene rearrangements in 52 cancer genes with therapeutic relevance. Two independent patient cohorts were investigated to define the workflow, turnaround times, feasibility, and reliability of OFA targeted sequencing in clinical application and using archival material.

View Article and Find Full Text PDF